Global Biopharmaceutical and Bio-CDMO Market Growth (Status and Outlook) 2025-2031

According to this study, the global Biopharmaceutical and Bio-CDMO market size will reach US$ 66310 million by 2031.

Biopharmaceutical Contract Development and Manufacturing Organizations (CDMOs) are companies that provide comprehensive services for the development and manufacturing of biopharmaceutical products. These organizations play a crucial role in the biopharmaceutical industry by offering a range of services to biotech and pharmaceutical companies, allowing them to outsource various stages of the drug development and manufacturing process.

Increasing Demand for Biologics: The rising demand for biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and gene therapies, is a significant driver. Biologics are increasingly becoming a focus for drug development due to their effectiveness in treating various diseases.

Cost-Effective Outsourcing: Outsourcing to CDMOs allows pharmaceutical and biotech companies to reduce capital expenditures, mitigate risks, and achieve cost savings. CDMOs offer specialized facilities and expertise, allowing clients to avoid the need for extensive in-house infrastructure.

Strategic Partnerships and Collaborations: Pharmaceutical and biotech companies increasingly engage in strategic partnerships with CDMOs to access specialized capabilities, share development risks, and benefit from the CDMO's expertise in specific technologies or therapeutic areas.

To meet the growing demand for biopharmaceuticals, CDMOs are investing in expanding their biomanufacturing capacities. This includes the construction of new facilities and the acquisition of advanced technologies to increase production capabilities.

The increasing interest and investment in cell and gene therapies have led to a rise in demand for CDMOs offering services in this area. Companies are seeking expertise in cell line development, viral vector production, and other specialized services related to advanced therapies.

Biopharmaceutical CDMOs are expanding their global presence to cater to the needs of a geographically diverse client base. This includes establishing facilities in key regions and forming strategic partnerships to enhance their global reach.

CDMOs are expanding their service offerings to provide integrated solutions covering the entire biopharmaceutical development and manufacturing lifecycle. This integrated approach aims to streamline processes and accelerate time to market for clients.

LPI (LP Information)' newest research report, the “Biopharmaceutical and Bio-CDMO Industry Forecast” looks at past sales and reviews total world Biopharmaceutical and Bio-CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Biopharmaceutical and Bio-CDMO sales for 2025 through 2031. With Biopharmaceutical and Bio-CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biopharmaceutical and Bio-CDMO industry.

This Insight Report provides a comprehensive analysis of the global Biopharmaceutical and Bio-CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Biopharmaceutical and Bio-CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biopharmaceutical and Bio-CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biopharmaceutical and Bio-CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biopharmaceutical and Bio-CDMO.

This report presents a comprehensive overview, market shares, and growth opportunities of Biopharmaceutical and Bio-CDMO market by product type, application, key players and key regions and countries.

Segmentation by Type:
Cell and Gene Therapies
Antibodies
Vaccines
Other

Segmentation by Application:
SMBs
Large Companies

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Lonza
Catalent
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
Boehringer Ingelheim
WuXi Biologics
Recipharm
Thermo Fisher Scientific
AGC Biologics
Rentschler Biopharma
KBI Biopharma
Siegfried
Aenova Group
GenScript
ProBioGen
Northway Biotech
3P Biopharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver. Show more